| Literature DB >> 28335391 |
Hui Lei1, Xiuping Lin2, Li Han3, Jian Ma4, Qingjuan Ma5, Jialiang Zhong6, Yonghong Liu7, Tiemin Sun8, Jinhui Wang9, Xueshi Huang10.
Abstract
Four new compounds, including two isocoumarins, pestaloisocoumarins A and B (1, 2), one sesquiterpenoid degradation, isopolisin B (4), and one furan derivative, pestalotiol A (5), together with one known isocoumarin, gamahorin (3), and three chlorinated benzophenone derivatives, pestalachloride B (6), pestalachloride E (7) and a mixture of pestalalactone atropisomers (8a/8b), were isolated from a culture of the fungus Pestalotiopsis heterocornis associated with sponge Phakellia fusca. These new chemical structures were established using NMR and MS spectroscopic data, as well as single-crystal X-ray crystallographic analysis and CD Cotton effects. All of the isolated compounds were evaluated for their antimicrobial and cytotoxic activities. Isocoumarins 1-3, showed antibacterial activities against Gram-positive bacteria Staphylococcus aureus and Bacillus subtilis with MIC values ranging from 25 to 100 μg/mL and weak antifungal activities. Chlorinated benzophenone derivatives 6-8 exhibited antibacterial activities against S. aureus and B. subtilis with MIC values ranging from 3.0 to 50 μg/mL and cytotoxicities against four human cancer cell lines with IC50 values of 6.8-87.8 μM.Entities:
Keywords: Pestalotiopsis heterocornis; antibacterial activity; antifungal activity; cytotoxicity; isocoumarin
Mesh:
Substances:
Year: 2017 PMID: 28335391 PMCID: PMC5367026 DOI: 10.3390/md15030069
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Structures of Compounds 1–8.
1H nuclear magnetic resonance (NMR) (600 MHz) and 13C NMR (150 MHz) data for Compounds 1 and 2 in CD3OD.
| 1 | 2 | |||
|---|---|---|---|---|
| Position | ||||
| 1 | 168.9, C | 169.0, C | ||
| 3 | 78.0, CH | 4.90, q (6.6) | 82.5, CH | 4.60, q (6.6) |
| 4 | 71.3, C | 67.9, C | ||
| 4a | 139.2, C | 145.3, C | ||
| 5 | 115.3, CH | 7.05, d (7.5) | 114.2, CH | 7.16, d (7.7) |
| 6 | 136.9, CH | 7.47, d (7.5) | 136.2, CH | 7.64, d (7.7) |
| 7 | 125.7, C | 123.6, C | ||
| 8 | 159.5, C | 159.4, C | ||
| 8a | 106.1, C | 106.4, C | ||
| 9 | 13.6, CH3 | 1.36, d (6.6) | 13.5, CH3 | 1.43, d (6.6) |
| 10 | 65.7, CH2 | 3.81, d (11.7) | 23.6, CH3 | 1.57, s |
| 11 | 14.0, CH3 | 2.24, s | 60.3, CH2 | 5.17, s |
| AcO | 171.1, C | |||
| 19.2, CH3 | 2.08, s | |||
Figure 2Single crystal X-ray structure of 1.
Figure 3Electronic circular dichroism (ECD) spectra of 1 and 2.
1H NMR (600 MHz) and 13C NMR (150 MHz) data for Compounds 4 and 5.
| 4 (in CD3OD) | 4 (in CDCl3) | 5 (in CD3OD) | ||||
|---|---|---|---|---|---|---|
| Position | ||||||
| 1 | 134.4, C | 134.7, C | 16.7, CH3 | 1.75, dd (6.4, 1.5) | ||
| 2 | 123.5, CH | 5.57, brd (5.0) | 124.2, CH | 5.57, brd (4.4) | 130.4, CH | 5.78, dd (14.7, 6.6) |
| 3 | 26.1, CH2 | 2.10, m 1.81, m | 26.5, CH2 | 2.12, m 1.82, m | 126.3, CH | 5.60, brdd (14.7, 7.2) |
| 4 | 37.2, CH | 2.06, m | 37.4, CH | 2.03, m | 82.9, CH | 4.13, d (7.9) |
| 5 | 32.3, CH2 | 1.95, brd (13.0) | 32.5, CH2 | 1.97, brd (13.2) | 81.6, C | |
| 6 | 67.1, CH | 4.00, brs | 68.0, CH | 4.07, brs | 82.7, CH | 3.75, d (4.5) |
| 7 | 89.0, C | 88.3, C | 84.7, CH | 3.58, td (6.6, 4.5) | ||
| 8 | 30.5, CH2 | 2.24, ddd | 31.2, CH2 | 2.19, ddd | 35.9, CH2 | 1.65, m |
| 9 | 28.4, CH2 | 2.72, ddd | 29.0, CH2 | 2.65, ddd | 18.9, CH2 | 1.50, m 1.42, m |
| 10 | 178.1, C | 176.7, C | 13.0, CH3 | 0.96, t (7.4) | ||
| 11 | 19.6, CH3 | 1.78, s | 20.8, CH3 | 1.80, s | 62.6, CH2 | 3.69, d (11.3) |
| 12 | 21.5, CH3 | 1.37, s | 23.1, CH3 | 1.37, s | ||
| OH | 3.65, brs | |||||
Figure 41H-1H COSY (correlation spectroscopy) HMBC (heteronuclear multiple-bond correlation spectroscopy) correlations of 5 and NOE (nuclear overhauser effect) correlations of 4 and 5. Fragment I: -CH-CH=CH-CH3; Fragment II: -CH(OH)CHCH2CH2CH3; Fragment III: The moiety in the blue dotted line box.
Cytotoxic activities of Compounds 6–8 (half maximal inhibitory concentration, IC50 in μM).
| Compound | BGC-823 | H460 | PC-3 | SMMC-7721 |
|---|---|---|---|---|
| 6.8 | 23.6 | 28.1 | 7.9 | |
| 48.0 | 87.8 | 55.1 | 40.2 | |
| 53.8 | 48.2 | 66.1 | 41.5 | |
| Adriamycin | 1.5 | 1.0 | 1.8 | 2.2 |
Antimicrobial activities of Compounds 1–3, 6–8 (minimum inhibitory concentration, MIC μg/mL).
| MIC | 1 | 2 | 3 | 6 | 7 | 8a/8b | Control |
|---|---|---|---|---|---|---|---|
| 50 | 25 | 100 | 3 | 50 | 50 | 0.25 | |
| 25 | 25 | 100 | 3 | 25 | 50 | 0.13 | |
| - | - | - | - | - | - | 0.13 | |
| 100 | - | - | - | - | - | 1.0 | |
| 100 | - | 100 | - | - | - | 2.0 | |
| 100 | 100 | 100 | - | - | - | 2.0 |
Ciprofloxacin; Amphotericin B.